Media Summary: This presentation provided an overview of the FDA Product-Specific Guidance (PSG) This presentation presented best practices from the Regulatory Business Process Manager (RBPM) perspective and covered ... This presentation provided a PLAIR overview and explained product eligibility requirements, along with OGD's PLAIR process for ...
Gdf 2024 D1s14 Anda Program - Detailed Analysis & Overview
This presentation provided an overview of the FDA Product-Specific Guidance (PSG) This presentation presented best practices from the Regulatory Business Process Manager (RBPM) perspective and covered ... This presentation provided a PLAIR overview and explained product eligibility requirements, along with OGD's PLAIR process for ... This presentation addressed strategies for improving sterility assurance applications submitted to the FDA. requirements. This presentation described the role of Pharmacology/Toxicology (Pharm/Tox) review in the Office of Generic Drugs (OGD) and ... This video examined facility assessment approaches for pre-marketing applications, covering both traditional inspections and ...
This presentation explored the Generic Drug Science and Accessibility-Bioequivalence (GDSA-BE) initiative and its role in ... This presentation examined post-approval changes in complex generics from drug product and Chemistry, Manufacturing, and ... This presentation described the purpose and scope of pre- This presentation explained how prescription (Rx) drug products may initiate marketing status changes to over-the-counter (OTC) ... This presentation identified FDA resources to assist with the Bio-IND process and provided an analysis of common clinical safety ... This presentation explained the rationale and importance of excipient safety evaluation in pediatric populations for generic drugs.
This presentation described the Emerging Technology The first of four Q&A discussion panels for day two of the Generic Drug Forum This presentation provided an overview of the pre- The first of three Q&A discussion panels for day one of the Generic Drug Forum This presentation provided key principles for comparative analyses (CA) and established understanding of essential CA ...
